Thromboembolism in Heart Failure, Old Ideas and New Challenges
Key result
Antithrombotic therapy lacks clear evidence in unselected HF but ischemic patients remain potential targets.
Why the study?
Does antithrombotic therapy prevent thromboembolic complications in patients with congestive heart failure?
Population
Patients with congestive heart failure, particularly those with ischemic heart failure
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Does not support routine antithrombotic therapy in unselected HF; leaves open targeted trials in ischemic subgroups.
Structured PICO
Does antithrombotic therapy prevent thromboembolic complications in patients with congestive heart failure?
P
Population
Patients with congestive heart failure, particularly those with ischemic heart failure
I
Intervention
Antithrombotic therapy / anticoagulation
O
Outcome
Thromboembolic complications (stroke, peripheral or pulmonary embolism, other thrombotic complications)
Routine anticoagulation is not justified for unselected heart failure patients due to low thromboembolic risk, but those with ischemic heart failure may benefit.
Cite This Study
Isnard et al. (2001) conducted a review in congestive heart failure. antithrombotic therapy was evaluated. Antithrombotic therapy in unselected patients with congestive heart failure lacks codified evidence, though patients with ischemic heart failure may represent potential targets for treatment.